The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.
D. C. Cho
No relevant relationships to disclose
E. I. Heath
No relevant relationships to disclose
J. M. Cleary
No relevant relationships to disclose
E. L. Kwak
Research Funding - Synta
L. Gandhi
No relevant relationships to disclose
D. P. Lawrence
No relevant relationships to disclose
C. Zack
No relevant relationships to disclose
F. Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
R. Bradley
Employment or Leadership Position - Synta
Stock Ownership - Synta
M. D. Karol
Employment or Leadership Position - Synta
Stock Ownership - Synta
G. Shapiro
Research Funding - Synta
P. LoRusso
Research Funding - Synta